medigraphic.com
ISSN 1817-5996 (Electronic)

2022, Number 1

<< Back Next >>

Rev Cub de Reu 2022; 24 (1)

Factors associated with the appearance of subclinical atherosclerosis in systemic lupus erythematosus

Hernández MY, Dedieu MD, Pozo ASM, Carrillo RC, Mederos CA

Language: Spanish
References: 34
Page:
PDF size: 323.97 Kb.


ABSTRACT

Introduction: Systemic lupus erythematosus is an inflammatory, chronic, multisystemic disease, which is defined by its multiple clinical features and by the almost invariable presence of autoantibodies directed against one or more components of the cell nucleus.
Objective: To characterize patients with Systemic Lupus Erythematosus and to identify its possible relationship with subclinical atherosclerosis.
Methods: A descriptive cross-sectional study of patients diagnosed with Systemic Lupus Erythematosus, treated at the Rheumatology Center in Havana, was carried out during the period from October 2015 to October 2017. The sample was non-probabilistic and consisted of 50 patients. Descriptive and inferential statistics were used.
Results: Of the total number of patients, 54.0% (n=27) had subclinical atherosclerosis. The traditional risk factors that showed association with the presence of plaque in patients with SLE were hypercholesterolemia, 70.4% (n=19) and hypertriglyceridemia 55.6% (n=15). A relationship was observed between the time of evolution, the presence of accumulated damage, renal compromise, CRP figures and accumulated dose of steroids, with the presence of subclinical atherosclerosis.
Conclusions: A higher average age was found in patients with SLE and presence of plaque. The traditional risk factors that showed association with the presence of atherosclerotic plaque were hypercholesterolemia and hypertriglyceridemia. An association was found between the time of evolution, the presence of accumulated damage, renal compromise, CRP figures and the accumulated dose of steroids, with the presence of plaque. In the study patients, the use of chloroquine was associated with the absence of subclinical atherosclerosis.


REFERENCES

  1. Battagliotti CA, Kilstein J, Gentiletti AA, Pons Estel B. Lupus Eritematoso Sistémico. Aspectos clínicos y terapéuticos. 2da. ed. Buenos Aires: Ed: CBE editores; 1998. p. 187-94.

  2. Petri M. La cohorte de lupus de Hopkins. Puesta al día. Clínic Rheumatic Disease North America (edición española). 2000;(2):203-17.

  3. Font J, Khamashta M, Vilardell M. Lupus eritematoso sistémico. Segunda parte, Capítulo VI. Barcelona: Ed. MRA, S.L.; 1996. p. 73-239.

  4. Hetjmancik MR, Wright IJC, Quint R, Jennings FL. The cardiovascular manifestations of systemic lupus erythematosus. Am Heart J. 1964;68(1):119-30.

  5. Rahman P, Urowitz MB, Gladman DD, Bruce IN, Genest J. Contribution of tradicional risk factors to coronary artery disease in patients with systemic lupus erythematosus. J Rheumatol. 1999 [Acceso 15/05/2017];26(11):2363-8. Disponible en: Disponible en: https://pubmed.ncbi.nlm.nih.gov/10555892/

  6. Grundy SM, Cleeman JI, Daniels SR, Donato KA, Eckel RH, Franklin BA, et al. Diagnosis and management of the metabolic syndrome: An American Heart Association/National Heart, Lung, and Blood Institute Scientific Statement. Circulation. 2005 [Acceso 15/05/2017];112(17):2735-52. Disponible en: Disponible en: https://www.ahajournals.org/doi/10.1161/CIRCULATIONAHA.105.169404

  7. Cistermas M. Ateroesclerosis en enfermedades reumatológicas. ¿Mito o realidad? Reumatología. 2006 [Acceso 15/05/2017];22(1):9-13. Disponible en: Disponible en: https://pesquisa.bvsalud.org/portal/resource/pt/lil-452444

  8. Esdaile JM, Abrahamowicz M, Grodzicky T, Li Y, Panaritis C, du Berger R, et al. Traditional Framingham risk factors fail to fully account for accelerated atherosclerosis in systemic lupus erythematosus. Arthritis Rheum. 2001 [Acceso 03/05/2017];2001(10):2331-7. Disponible en: Disponible en: https://pubmed.ncbi.nlm.nih.gov/11665973/

  9. Liang MH, Socher SA, Roberts WN, Esdaile JM. Measurements of systemic lupus erythematosus activity in clinical research. Arthritis Rheum. 1988 [Acceso 03/05/2017];31(7):817-25. Disponible en: Disponible en: https://onlinelibrary.wiley.com/doi/abs/10.1002/art.1780310701

  10. Hernández Muñiz Y, Guibert Toledano ZM, Reyes Llerena GA. Correlación de las cifras de proteína C reactiva y aterosclerosis en pacientes con lupus eritematoso sistémico. Rev Cubana Reumatol. Ago 2015 [Acceso 03/05/2017];17(2):[aprox. 5 p.]. Disponible en: Disponible en: http://www.revreumatologia.sld.cu/index.php/reumatologia/article/view/414/pdf_18

  11. Tan EM, Cohen AS, Fries JF, Masi AT, Mcshane DJ, Rothfield NF, et al. The 1982 revised criteria for the classification of systemic lupus erythematosus. Arthritis Rheum [Internet]. 1982 [Acceso 03/05/2017];25(11):1271-7. Disponible en: Disponible en: https://onlinelibrary.wiley.com/doi/abs/10.1002/art.1780251101

  12. Doria A, Shoenfield Y, Wu R, Gambari PF, Puato M, Ghirardello A, et al. Risk factors for subclinical atherosclerosis in a prospective cohort of patients with systemic lupus erythematosus. Ann Rheum Dis. 2003 [Acceso 03/05/2017];62(11):1071-7. Disponible en: Disponible en: https://pubmed.ncbi.nlm.nih.gov/14583570/

  13. Manzi S, Meilahn EN, Rairie JE, Conte CG, Medsger TA, Jansen-McWilliams, et al. Age-specific Incidente Rates of Myocardial Infarction and Angina in Women with Systemic Lupus Erythematosus: Comparison with the Framingham Study. Am J Epidemiol. 1997 [Acceso 03/05/2018];145(5):408-15. Disponible en: Disponible en: https://academic.oup.com/aje/article-abstract/145/5/408/120887

  14. Petri M, Roubenoff R, Dallal GE, Nadeau MR, Selhub J, Rosenberg I. Plasma homocysteine as a risk factor for atherothrombotic events in systemic lupus erythematosus. Lancet. 1996 [Acceso 03/05/2018];348(9035):1120-4. Disponible en: Disponible en: https://www.sciencedirect.com/science/article/abs/pii/S0140673696030322

  15. Abu-Shakra M, Urowitz MB, Gladman DD, Gough J. Mortality studies in systemic lupus erythematosus. Results from a single center. I. Causes of death. J Rheumatol. 1995 [Acceso 03/05/2018];22(7):1259-64. Disponible en: Disponible en: https://europepmc.org/article/med/7562755

  16. Guibert Toledano ZM, Reyes Llerena GA, Hernández Muñiz Y, Ugarte Moreno D, Miñoso Arafi Y. Morbilidad cardiovascular y evaluación de aterosclerosis en pacientes con lupus eritematoso sistémico. Rev Cubana Reumatol. Ago 2016 [Acceso 03/05/2018];18(2):[aprox. 7 p.]. Disponible en: Disponible en: http://scielo.sld.cu/scielo.php?script=sci_arttext&pid=S181759962016000200002&lng=es

  17. Estévez del Toro M, Chico Capote A, Barahona Jorge RA, Jiménez Paneque R, Hernández Castro J. Prevalencia de enfermedad vascular aterosclerótica en pacientes cubanos con lupus eritematoso sistémico. Reumatol Clin. 2008 [Acceso 03/05/2018];4(1):13-8. Disponible en: Disponible en: https://www.sciencedirect.com/science/article/pii/S1699258X0871790X

  18. Duarte C, Couto M, Vaz C, Ines L, Malcata A. Perfil de risco cardiovascular numapopulação portuguesa de doentescom LES. Acta Reumatol Port. 2009 [Acceso 03/05/2018];34(2):349-57. Disponible en: Disponible en: http://hdl.handle.net/10400.4/630

  19. Rodríguez Hernández R, Alberteris Rodríguez A, López Báster J, Diéguez Martínez M, Miguel-Soca PE, Cutié Anido Y. Factores de riesgo asociados a hipertensión arterial en pacientes con lupus eritematoso sistémico. Holguín, Cuba. Rev Haban Cienc Méd. Dic 2017 [Acceso 03/05/2018];16(6):[aprox. 4 p.]. Disponible en: Disponible en: http://scielo.sld.cu/scielo.php?script=sci_arttext&pid=S1729519X2017000600011&lng=es

  20. Lahoz C, Mostaza JM. La aterosclerosis como enfermedad sistémica. Rev Esp Cardiol. 2007 [Acceso 03/05/2018];60(2):184-95. Disponible en: Disponible en: https://www.sciencedirect.com/science/article/abs/pii/S0300893207750091

  21. Stamler J, Wentworth D, Neaton JD. Is relationship between serum cholesterol and risk of premature death from coronary heart disease continuous and graded? Findings in 356,222 primary screenees of the Multiple Risk Factor Intervention Trial (MRFIT). JAMA [Internet]. 1986 [Acceso 03/05/2018];256:2823-8. Disponible en:Disponible en:https://jamanetwork.com/journals/jama/article-abstract/363231

  22. Kannel WB, Castelli WP, Gordon T, Mc Namara PM. Serum cholesterol, lipoproteins, and the risk of coronary heart disease. The Framingham study. Ann Intern Med. 1971 [Acceso 03/05/2018];74:1-12. Disponible en: Disponible en: https://www.acpjournals.org/doi/abs/10.7326/0003-4819-74-1-1

  23. Baigent C, Keech A, Kearney PM, Blackwell L, Buck G, Pollicino C, et al. Efficacy and safety of cholesterol-lowering treatment: prospective meta-analysis of data from 90,056 participants in 14 randomised trials of statins. Lancet. 2005 [Acceso 03/05/2018];366:1267-78. Disponible en: Disponible en: https://www.thelancet.com/journals/lancet/article/PIIS0140673605673941/fulltext

  24. Cacciapaglia F, Zardi EM, Coppoloni G, Buzzulini F, Margiotta D, Arcarece L, et al. Stiffness parameters, intima-media thickness and early aterosclerosis in systemic lupus erythematosus patients. Lupus. 2009 [Acceso 03/05/2018];18(3):249-56. Disponible en: Disponible en: https://journals.sagepub.com/doi/abs/10.1177/0961203308097571

  25. Urowitz MB, Bookman AA, Koehler BE, Gordon DA, Smytheet HA, Ogryzlo MA. The bimodal mortality pattern of systemic lupus erythematosus. Am J Med. 1976 [Acceso 03/05/2018];60(2):221-5. Disponible en: Disponible en: https://www.sciencedirect.com/science/article/abs/pii/0002934376904319

  26. Rubin LA, Urowitz MB, Gladman DD. Mortality in systemic lupus erythematosus: the bimodal mortality pattern revisited. QJM. 1985 [Acceso 03/05/2018>;55(1):87-98. Disponible en: Disponible en: https://academic.oup.com/qjmed/article-abstract/55/1/87/1512652

  27. Bruce IN, Urowitz MB, Gladman DD, Ibañez D, Steiner G. Risk factors for coronary heart disease in women with systemic lupus erythematosus: The Toronto Risk Factor Study. Arthritis Rheum. 2003 [Acceso 03/05/2018];48(11):3159-67. Disponible en: Disponible en: https://onlinelibrary.wiley.com/doi/full/10.1002/art.11296

  28. Silvariño R, Inoue Sato E. Factores de riesgo para aterosclerosis en enfermedades autoinmunitarias sistémicas. Rev Med Urug. 2008 [Acceso 03/05/2018];24(2):118-32. Disponible en: Disponible en: http://www.scielo.edu.uy/scielo.php?script=sci_arttext&pid=S168803902008000200007

  29. Johansson E, Forsberg K, Johnsson H. Clinical and experimental evaluation of the thromboprophylactic effect of hydroxychloroquine sulfate after total hip replacement. Haemostasis. 1981 [Acceso 03/05/2018];10(2):89-96. Disponible en: Disponible en: https://www.karger.com/Article/Abstract/214391

  30. Prowse C, Pepper D, Dawes J. Prevention of the platelet alphagranule release reaction by membrane-active drugs. Thromb Res. 1982 [Acceso 03/05/2018];25(3):219-27. Disponible en: Disponible en: https://www.sciencedirect.com/science/article/abs/pii/0049384882902419

  31. van Halm VP, Nurmohamed MT, Twisk JW, Dijkmans BA, Voskuyl AE. Disease modifying antirheumatic drugs are associated with a reduced risk for cardiovascular disease in patients with rheumatoid arthritis: a case control study. Arthritis Res Ther. 2006 [Acceso 03/05/2018];8(5):[aprox. 10 p.]. Disponible en: Disponible en: https://arthritis-research.biomedcentral.com/articles/10.1186/ar2045

  32. del Rincón I, O’Leary DH, Haas RW, Escalante A. Effect of glucocorticoids on the arteries in rheumatoid arthritis. Arthritis Rheum. 2004 [Acceso 03/05/2018];50(12):[aprox. 15 p.]. Disponible en: Disponible en: https://onlinelibrary.wiley.com/doi/full/10.1002/art.20661

  33. Solomon DH, Karlson EW, Rimm EB, Cannuscio CC, Mandl LA, Manson JE, et al. Cardiovascular morbidity and mortality in women diagnosed with rheumatoid arthritis. Circulation. 2003 [Acceso 03/05/2018];107(9):1303-7. Disponible en: Disponible en: https://www.ahajournals.org/doi/abs/10.1161/01.CIR.0000054612.26458.B2

  34. Gladman DD, Urowitz MB. Morbidity in systemic lupus erythematosus. J Rheumatol. 1987 [Acceso 03/05/2018];14(Suppl. 13):223-6. Disponible en: Disponible en: https://pubmed.ncbi.nlm.nih.gov/3612650/




2020     |     www.medigraphic.com